Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;13(Suppl 3):199-203.
doi: 10.22088/cjim.13.0.199.

0Effects of the COVID-19 Pandemic on Treatment Adherence in Patients with Chronic Heart Failure

Sergey Yu Martsevich  1 , Yulia V Lukina  1 , Natalia P Kutishenko  1 , Elmira T Guseynova  1
Affiliations

0Effects of the COVID-19 Pandemic on Treatment Adherence in Patients with Chronic Heart Failure

Sergey Yu Martsevich et al. Caspian J Intern Med. 2022.

Abstract

Background: To assess the influence of the COVID-19 (Coronavirus Disease 2019) pandemic on treatment adherence by patients with CHF (Chronic heart failure) and to determine the factors associated with changing adherence during home-isolation.

Methods: The survey was conducted in patients participating in the COMPLIANCE study (ClinicalTrials.gov. NCT04262583). Thirty-one patients, included into in the COMPLIANCE study before March 1, 2020, were interviewed through phone calls. A modified adherence scale of the National Society for Evidence-Based Pharmacotherapy was used, which permits to assess of overall adherence, adherence to particular drugs and the main causes for non-adherence.

Results: In the whole group of patients, only a tendency to reduced overall adherence was registered during the COVID-19 pandemic (р=0,256). Significant differences in the rate of adherence deterioration were revealed for angiotensin-converting enzyme (ACE) inhibitors (p=0.031) and for statins (p=0.002). The reasons for non-adherence were lack of opportunity to contact with a physician, inability to perform investigations necessary for correcting prescribed pharmacotherapy, and side effects.

Conclusion: A tendency to deterioration of adherence to prescribed pharmacotherapy was revealed during the COVID-19 pandemic. A significant decline in adherence was registered to ACE inhibitors and statins.

Keywords: COVID-19 pandemic; adherence to treatment; chronic heart failure; factors of non-adherence; period of home isolation.

PubMed Disclaimer

Conflict of interest statement

none

Figures

Figure 1
Figure 1
Dynamics of overall treatment adherence (NODPh adherence scale) Dynamics of overall treatment adherence before and during the pandemic COVID-19 (n=31)
Figure 2
Figure 2
Dynamics of adherence to specific drugs
See this image and copyright information in PMC

References

    1. Zheng SQ, Yang L, Zhou PX, et al. Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective. Res Social Adm Pharm. 2021;17:1819–24. - PMC - PubMed
    1. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol . 2020;75:2352–71. - PMC - PubMed
    1. de Joode K, Dumoulin DW, Engelen V, et al. Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective. Eur J Cancer. 2020;136:132–9. - PMC - PubMed
    1. Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J . 2020;41:1801–3. - PMC - PubMed
    1. Vakirlis E, Bakirtzi K , Papadimitriou I, et al. Treatment adherence in psoriatic patients during COVID‐19 pandemic: Real‐world data from a tertiary hospital in Greece. J Eur Acad Dermatol Venereol. 2020;34:e673–e675. - PMC - PubMed

Associated data

LinkOut - more resources